Serge A Jabbour1, Juan P Frías2, Azazuddin Ahmed3, Elise Hardy4, Jasmine Choi5, C David Sjöström6, Cristian Guja7. 1. Thomas Jefferson University, Philadelphia, PA serge.jabbour@jefferson.edu. 2. National Research Institute, Los Angeles, CA. 3. Apex Medical Research, Chicago, IL. 4. AstraZeneca, Gaithersburg, MD. 5. Statum Research, Irvine, CA. 6. AstraZeneca, Gothenburg, Sweden. 7. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Abstract
OBJECTIVE: In patients with type 2 diabetes uncontrolled withmetformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In this study, we investigated efficacy and safety at 104 weeks after randomization. RESEARCH DESIGN AND METHODS: DURATION-8 was a 104-week, multicenter, double-blind, randomized, active-controlled, phase 3 trial. In total, 695 adults (aged ≥18 years) with type 2 diabetes and inadequate glycemic control (HbA1c 8.0-12.0% [64-108 mmol/mol]) despite stable metformin monotherapy (≥1,500 mg/day) were randomly assigned (1:1:1) to receive exenatide 2 mg QW plus once-daily dapagliflozin 10 mg, exenatide QW plus placebo, or dapagliflozin plus placebo. All 104-week evaluations were exploratory. RESULTS: At week 104, 431 (62.0%) patients completed treatment. The adjusted least squares mean change (SE) from baseline to week 104 in HbA1c was greater with exenatide QW plus dapagliflozin (-1.70% [0.11]) versus exenatide QW plus placebo (-1.29% [0.12]; P = 0.007) and dapagliflozin plus placebo (-1.06% [0.12]; P < 0.001). Clinically relevant changes in FPG, 2-h PPG, weight, and SBP were also observed with exenatide QW plus dapagliflozin. There were no unexpected safety findings, and exenatide QW plus dapagliflozin was well tolerated, with no episodes of major hypoglycemia. CONCLUSIONS: In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings.
RCT Entities:
OBJECTIVE: In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In this study, we investigated efficacy and safety at 104 weeks after randomization. RESEARCH DESIGN AND METHODS: DURATION-8 was a 104-week, multicenter, double-blind, randomized, active-controlled, phase 3 trial. In total, 695 adults (aged ≥18 years) with type 2 diabetes and inadequate glycemic control (HbA1c 8.0-12.0% [64-108 mmol/mol]) despite stable metformin monotherapy (≥1,500 mg/day) were randomly assigned (1:1:1) to receive exenatide 2 mg QW plus once-daily dapagliflozin 10 mg, exenatide QW plus placebo, or dapagliflozin plus placebo. All 104-week evaluations were exploratory. RESULTS: At week 104, 431 (62.0%) patients completed treatment. The adjusted least squares mean change (SE) from baseline to week 104 in HbA1c was greater with exenatide QW plus dapagliflozin (-1.70% [0.11]) versus exenatide QW plus placebo (-1.29% [0.12]; P = 0.007) and dapagliflozin plus placebo (-1.06% [0.12]; P < 0.001). Clinically relevant changes in FPG, 2-h PPG, weight, and SBP were also observed with exenatide QW plus dapagliflozin. There were no unexpected safety findings, and exenatide QW plus dapagliflozin was well tolerated, with no episodes of major hypoglycemia. CONCLUSIONS: In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings.
Authors: Søren L Kristensen; Rasmus Rørth; Pardeep S Jhund; Kieran F Docherty; Naveed Sattar; David Preiss; Lars Køber; Mark C Petrie; John J V McMurray Journal: Lancet Diabetes Endocrinol Date: 2019-08-14 Impact factor: 32.069
Authors: Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine Journal: Lancet Date: 2018-11-10 Impact factor: 79.321
Authors: Bernard Zinman; Vaishali Bhosekar; Robert Busch; Ingrid Holst; Bernhard Ludvik; Desirée Thielke; James Thrasher; Vincent Woo; Athena Philis-Tsimikas Journal: Lancet Diabetes Endocrinol Date: 2019-03-01 Impact factor: 32.069
Authors: Serge A Jabbour; Juan P Frías; Elise Hardy; Azazuddin Ahmed; Hui Wang; Peter Öhman; Cristian Guja Journal: Diabetes Care Date: 2018-08-06 Impact factor: 19.112
Authors: Bernhard Ludvik; Juan P Frías; Francisco J Tinahones; Julio Wainstein; Honghua Jiang; Kenneth E Robertson; Luis-Emilio García-Pérez; D Bradley Woodward; Zvonko Milicevic Journal: Lancet Diabetes Endocrinol Date: 2018-02-23 Impact factor: 32.069
Authors: Per Lundkvist; Maria J Pereira; Petros Katsogiannos; C David Sjöström; Eva Johnsson; Jan W Eriksson Journal: Diabetes Obes Metab Date: 2017-05-31 Impact factor: 6.577
Authors: Charlotte C van Ruiten; Dick J Veltman; Max Nieuwdorp; Richard G IJzerman Journal: Front Endocrinol (Lausanne) Date: 2022-05-04 Impact factor: 6.055
Authors: Charlotte C van Ruiten; Mark M Smits; Megan D Kok; Erik H Serné; Daniël H van Raalte; Mark H H Kramer; Max Nieuwdorp; Richard G IJzerman Journal: Cardiovasc Diabetol Date: 2022-04-28 Impact factor: 8.949
Authors: Ryan A Lafferty; Finbarr P M O'Harte; Nigel Irwin; Victor A Gault; Peter R Flatt Journal: Front Endocrinol (Lausanne) Date: 2021-05-18 Impact factor: 5.555